Welcome, Guest. Please login or register.
June 22, 2024, 03:04:42 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55129
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 71
Total: 71


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Emricasan Proves a Disappointment as NASH Treatment  (Read 8945 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Emricasan Proves a Disappointment as NASH Treatment
« on: December 16, 2019, 11:45:42 am »
Conatus Pharmaceuticals’ oral pan-caspase inhibitor emricasan proved disappointing as a potential treatment for non-alcoholic steatohepatitis (NASH) in a 72-week trial. The treatment did not meet its primary endpoint of an improvement in liver fibrosis (scarring) of at least one stage without any worsening of NASH.

Stephen A. Harrison, MD, of Pinnacle Clinical Research in San Antonio, presented findings from the trial at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, this week in Boston.

The randomized, placebo-controlled, double-blind study enrolled people at 87 sites in the United States, Spain and Germany. The participants had to have NASH, a non-alcoholic fatty liver disease activity score (NAS) of 4 or greater and a fibrosis stage of F1, F2 or F3. No more than 20% of the study population could have fibrosis Stage 1, and if they did, they also had to have diabetes or metabolic syndrome. If participants were taking vitamin E or pioglitazone, they had to be on a stable dose for at least three months.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.